About

About OpZira, Inc. OpZira, Inc. is a forward-thinking ophthalmic medical device company founded on a legacy of research excellence. The company delivers innovative technologies designed to enhance the detection and monitoring of ocular disease. OpZira’s creation follows Alcon’s acquisition of LumiThera and its Valeda® Light Delivery System, the first and only FDA-authorized treatment for dry AMD. AdaptDx Pro® measures dark adaptation speed. Impaired dark adaptation speed is a key early indicator of rod-mediated dysfunction, one of the first functional signs of retinal dysfuction AdaptDx Pro is available in the U.S. NOVA™ Vision Testing System is an electrophysiology platform that provides objective assessments of the visual and neuro-visual pathway. VEP is available in the U.S. and select international markets. ERG is available outside of the U.S. For more information, visit https://opzira.com. AdaptDx Pro and NOVA are available through AdaptDx, Inc. and Diopsys, Inc., respectively.